[CASE REPORT]

Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus

Misato Jono, Yuhei Kinehara, Yoshihiko Utsu, Yoshiro Tamura, Masahiro Koseto, Teruaki Murakami, Akifumi Uota, Ruyusuke Ninomiya, Satoshi Komo, Satoru Sumitani, Bunzo Sato, Soji Kasayama and Isao Tachibana

Abstract:
The patient was a 73-year-old woman with lung adenocarcinoma and systemic lupus erythematosus (SLE) who was treated with pembrolizumab. After six cycles of pembrolizumab, she developed symptoms suggestive of neuropsychiatric SLE, such as resting tremor, confusional state, depression, mood disorder, and anxiety disorder. In addition, her cerebrospinal fluid level of interleukin-6 was elevated. Her symptoms resolved one month after the discontinuation of pembrolizumab. This is the first report of neuropsychiatric symptoms in a patient with lung cancer and SLE on immune checkpoint blockade therapy.

Key words: Neuropsychiatric immune-related adverse events with pembrolizumab, non-small cell lung cancer with SLE

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.3782-19)

Introduction

The development of immune checkpoint blockade (ICB) therapy represents dramatic progress in the treatment of advanced non-small cell lung cancer (NSCLC). Anti-programmed cell death 1 (PD-1) monoclonal antibodies (mAbs), such as nivolumab and pembrolizumab, and anti-programmed death-ligand 1 (PD-L1) mAbs, such as atezolizumab and durvalumab, counteract molecule-mediated immunosuppressive signals. They have become key immune checkpoint inhibitors (ICIs) (1-3). The addition of ICB therapy to standard chemotherapy has resulted in significantly longer overall survival and progression-free survival in comparison to chemotherapy alone in many patients with previously untreated metastatic NSCLC (4-6).

Despite their benefits, reports of immune-related adverse events (irAEs) in association with ICB therapy are accumulating (1, 2, 7). Although a multi-institutional retrospective analysis suggested that ICIs could be safely administered to patients with NSCLC and a history of autoimmune disease (AID) (8, 9), their safety and efficacy in patients with NSCLC and systemic lupus erythematosus (SLE) have not been extensively studied. We herein present the case of a patient with lung cancer and SLE who experienced neuropsychiatric symptoms after treatment with pembrolizumab, which was suspected to be an irAE similar to neuropsychiatric SLE (NPSLE).

Case Report

The patient was a 73-year-old woman who had been diagnosed with T4N2M1b adenocarcinoma of the lung in July 2017 (Fig. 1). At 68 years of age, she was diagnosed with SLE based on arthritis, pleuritis, and elevated levels of anti-nuclear and anti-dsDNA antibodies. She was being treated with prednisolone (5 mg/day) and tacrolimus (1 mg/day) at the time of the lung cancer diagnosis. Her tumor showed a high PDL-1 expression level (Tumor Proportion Score > 50%). She began pembrolizumab therapy in August 2017...
after the development of the severe irAE. At fifteen months after discontinuation, chest CT showed no recurrence of lung cancer (Fig. 1). The patient’s neuropsychiatric symptoms did not recur, even without specific additional treatment.

Discussion

NPSLE refers to neuropsychiatric involvement in SLE, which affects the central nervous system, peripheral nervous system, or both (10). NPSLE is clinically heterogeneous and therefore difficult to diagnose (11). The precise pathophysiology of NPSLE is not clearly understood. Due to a lack of specific diagnostic biomarkers, the diagnosis of NPSLE is still based on clinical observations, laboratory tests, and imaging techniques (12). For the diagnosis of NPSLE, the nomenclature system proposed by the American College of Rheumatology (ACR) in 1999 is widely accepted, which provides the criteria for 19 neuropsychiatric manifestations (13). Furthermore, infection, trauma, malignancy, and other neurological diseases should be ruled out (14). Among the manifestations listed by the ACR, our patient had acute confusional state, anxiety disorder, and mood disorder. Cerebrovascular events and cranial metastases were excluded based on CT and MRI findings.

Various autoantibodies might play different pathogenic roles in the development of NPSLE symptoms by targeting diverse cellular or tissue components. Autoantibodies can activate downstream signaling cascades, leading to the expression of various cytokines and chemokines (15). Elevation of IL-6 levels in the CSF (>4.3 pg/mL) is regarded as a highly
specific and sensitive finding for NPSLE (87.5% and 92.3%, respectively) (16). Our patient’s CSF IL-6 level was high (27.8 pg/mL), which might have been related to her neuropsychiatric manifestations. Thus, we presume that pembrolizumab was responsible for the progression of NPSLE-like symptoms in our patient.

PD-1 binds to its two ligands, PDL-1 and PDL-2, and mediates signals that prevent immune surveillance and autoimmunity by inactivating cytotoxic T cells (17). Blockade of PD-1 activates lymphocytes and might induce their transmigration into the central nervous system (CNS). Indeed, the increased transmigration of both of CD4 and CD8 T lymphocytes through endothelial cells was observed in blood vessels in the human brain after PDL-1 or PDL-2 blockade (18). In our patient, pembrolizumab might have induced the migration of lymphocytes into the CNS, leading to inflammation and the overproduction of cytokines including IL-6. Furthermore, Chipman et al. reported that IL-6 blockade was a therapeutic option for the management of steroid refractory irAE, including neuropsychiatric irAE (19), so it is conceivable that an increased IL-6 level is significantly associated with the development of irAEs, including neuropsychiatric irAEs. We believe that such neurological irAEs might result from pathophysiological mechanisms similar to those in NPSLE.

In a multi-institutional retrospective analysis, Giulia et al. reported that adverse events in patients with NSCLC and AID who were treated with ICIs were generally manageable. Among 56 patients with NSCLC and AID who received ICIs, 13 patients (23%) experienced an exacerbation of AID. Four of them were treated with systemic corticosteroids, but none required permanent discontinuation of ICIs (8). Likewise, Abdel-Wahab et al. reported that exacerbations of AID can be managed without discontinuing ICB therapy because many severe or fatal events resolve after the administration of systemic corticosteroids (20). Patients with SLE were included in these clinical studies, but no systemic or neurological exacerbations were reported. In our case, we decided to discontinue pembrolizumab. Despite this, the primary and metastatic tumors did not progress. Further studies are required to evaluate the safety and efficacy of ICIs in patients with NSCLC and SLE.

In conclusion, this is the first report of a patient with SLE who developed neurological irAEs after ICB therapy. Mechanisms similar to those in NPSLE could be involved. It is necessary to be aware of the risk of irAEs affecting the CNS when treating patients with NSCLC and SLE.

The authors state that they have no Conflict of Interest (COI).

References

1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Non-Squamous Non-Small-Cell Lung Cancer. N Engl J Med 373: 1627-1639, 2015.
2. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 375: 1823-1833, 2016.
3. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017.
4. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 378: 2078-2092, 2018.
5. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 379: 2040-2051, 2018.
6. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Non-Squamous NSCLC. N Engl J Med 378: 2288-2301, 2018.
7. Ricciuti B, Baglivo S, Pugliaiunga L, et al. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol 9: 387-404, 2017.
8. Leonardi GC, Gainor JF, Altan M, et al. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol 36: 1905-1912, 2018.
9. Richter MD, Pinkston O, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. Arthritis Rheumatol 70: 356-360, 2018.
10. Castellino G, Govoni M, Giacuzzo S, Trota F. Optimizing clinical
monitoring of central nervous system involvement in SLE. Autoimmun Rev 7: 297-304, 2008.

11. Sato S, Yashiro M, Asano T, Kobayashi H, Watanabe H, Migita K. Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 36: 1655-1659, 2017.

12. Kimura A, Kanoh Y, Sakurai T, et al. Antibodies in patients with neuropsychiatric systemic lupus erythematosus. Neurology 74: 1372-1379, 2010.

13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997.

14. Kassan SS, Lockshin MD. Central nervous system lupus erythematosus. The need for classification. Arthritis Rheum 22: 1382-1385, 1979.

15. Okamoto H, Kobayashi A, Yamanaka H. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. J Biomed Biotechnol 2010: 268436, 2010.

16. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol 28: 1319-1323, 2009.

17. Martin-Liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf 14: 957-964, 2015.

18. Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep 2016: 2016.

19. Chipman RG, Aparna H, Cynthia C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Practice 25: 551-557, 2019.

20. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review. Ann Intern Med 168: 121-130, 2018.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).